Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

BACKGROUND: Small cell lung cancer (SCLC) accounts for 15% of lung cancers, and the primary treatment of this malignancy is chemotherapy and radiotherapy. Delta-like 3 (DLL3) is an attractive target for SCLC immunotherapy since its expression is highly restricted to SCLC with a neglectable appearanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Amar, Norhan, Zhu, Yuankui, Wang, Chunguang, Xia, Chunjiao, Yang, Xiaoqing, Wu, Dongde, Feng, Mingqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304844/
https://www.ncbi.nlm.nih.gov/pubmed/32554616
http://dx.doi.org/10.1136/jitc-2020-000785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304844/
https://www.ncbi.nlm.nih.gov/pubmed/32554616
http://dx.doi.org/10.1136/jitc-2020-000785

Ejemplares similares